Skip to contentN
Nutra Pharma Corp
N
NPHCNutra Pharma Corp Q2 2017 · 10-Q
Revenue$33.18K$33.18K+8.1% vs Q2 2016 Net Income-$1.12M-$1.12MN/M vs Q2 2016 EPS Diluted$0.00$0.00N/M vs Q2 2016 Gross Profit$22,191+11.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nutra Pharma Corp · CIK 1119643 · Engraved from SEC EDGAR
Operating Cash Flowderived-$295,772N/M Margins · derivedGross margin66.9%+1.8 pt vs Q2 2016
Operating margin-1252.1%+732.1 pt vs Q2 2016
Net margin-3361.3%−1230.0 pt vs Q2 2016
ended Jun 30, 2017 · filed Aug 14, 2017 · 45 d after period end